Wednesday, June 08, 2016 2:01:35 PM
I believe anyone who reads this board can make their own decision
while evaluating the merit (if any) of the opinions rendered by both sides.
I am sure JNJ will flourish wonderfully even with the losses to DECN, and I really hope they do, as I opined earlier...
it just provides more in payment$ to DECN.
while evaluating the merit (if any) of the opinions rendered by both sides.
I am sure JNJ will flourish wonderfully even with the losses to DECN, and I really hope they do, as I opined earlier...
it just provides more in payment$ to DECN.
Recent JNJ News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/22/2026 08:02:41 PM
- Johnson & Johnson’s IMAAVY Demonstrates Durable Disease Control in Myasthenia Gravis • IH Market News • 04/22/2026 12:49:42 PM
- IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG) • PR Newswire (US) • 04/22/2026 12:05:00 PM
- Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference • Business Wire • 04/21/2026 08:22:00 PM
- Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026 • Business Wire • 04/21/2026 11:45:00 AM
- The Infrastructure Play Hiding in Plain Sight Across Cardiac Care • GlobeNewswire Inc. • 04/16/2026 03:00:00 PM
- Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference • Business Wire • 04/15/2026 08:11:00 PM
- Johnson & Johnson Beats Q1 Expectations, Lifts 2026 Outlook • IH Market News • 04/14/2026 12:42:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/14/2026 11:35:25 AM
- Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1% • Business Wire • 04/14/2026 10:21:00 AM
- Johnson & Johnson reports Q1 2026 results, raises 2026 outlook • Business Wire • 04/14/2026 10:20:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/13/2026 03:15:34 PM
- Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision • Business Wire • 04/10/2026 12:00:00 PM
- Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value • InvestorsHub NewsWire • 04/09/2026 01:00:00 PM
- Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value • GlobeNewswire Inc. • 04/09/2026 12:30:00 PM
- Johnson & Johnson introduces VARIPULSE Pro in Europe after CE Mark clearance • IH Market News • 04/07/2026 02:12:35 PM
- Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe • Business Wire • 04/07/2026 12:00:00 PM
- Royalty Pharma signs $500M co-development agreement with J&J • IH Market News • 03/30/2026 12:28:19 PM
- J&J reports one-year ICOTYDE psoriasis trial results show sustained efficacy • IH Market News • 03/30/2026 09:32:48 AM
- ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis • PR Newswire (US) • 03/28/2026 02:00:00 PM
- Nanobiotix Shares Surge After Report of Possible Johnson & Johnson Takeover Interest • IH Market News • 03/25/2026 02:00:48 PM
- FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide • PR Newswire (US) • 03/18/2026 11:49:00 AM
- Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer • PR Newswire (US) • 03/13/2026 04:35:00 PM

